The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2015 | An overview of daratumumab monotherapy for heavily treated multiple myeloma
Sagar Lonial
• 2 Jun 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, summarises the potential of the anti-CD38 monoclonal antibody, daratumumab, as a novel, well-tolerated, single-agent therapy for patients with heavily treated multiple myeloma.
